{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T16:40:54Z","timestamp":1770741654473,"version":"3.49.0"},"reference-count":28,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T00:00:00Z","timestamp":1749081600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Landspitali\u2014The National University Hospital of Iceland"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Direct-acting antiviral (DAA) therapy has been highly successful in treating chronic hepatitis C (CHC). The nationwide Treatment as Prevention of Hepatitis C (TraP HepC) initiative that was launched in Iceland in 2016 utilized liver stiffness measurements (LSM) to assess liver fibrosis at baseline and follow-up. We aimed to determine changes in liver stiffness among patients following treatment with DAAs and evaluate risk factors associated with hepatic fibrosis. Methods: Eligible CHC patients with liver stiffness of &gt;9.5 kilopascals (kPa) before DAA treatment were invited for a follow-up visit in 2024. Risk factors for cirrhosis were registered, LSM performed, and liver enzymes, blood lipids, and glucose levels measured. Changes in liver stiffness were compared to baseline measurements, and correlations with risk factors were analyzed. Results: A total of 96 patients had LSMs &gt; 9.5 kPa at treatment initiation. During the follow-up period, 61 were eligible for participation, 38 consented, and 34 (35%) died. The total follow-up was 258.3 person-years. The median follow-up period between measurements was 7.1 years. The median liver stiffness decreased from 17.2 kPa to 7.3 kPa (p &lt; 0.01), and 80% of those with cirrhosis (&gt;12.5 kPa) regressed to non-cirrhotic values. High BMI and daily alcohol consumption were significantly associated with increased liver stiffness in 8% of patients. Conclusions: In this single-arm, pre-post pilot study, liver stiffness regressed significantly in 92% of patients who were cured of CHC. Patients with other persistent risk factors following cure, such as obesity and alcohol abuse, were the only patients who had increased liver stiffness at the end of follow-up.<\/jats:p>","DOI":"10.3390\/jcm14113982","type":"journal-article","created":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T05:49:22Z","timestamp":1749102562000},"page":"3982","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinically Important Decrease in Liver Stiffness Following Treatment for Hepatitis C: Outcome of the TraP HepC Nationwide Elimination Program"],"prefix":"10.3390","volume":"14","author":[{"given":"Sm\u00e1ri Freyr","family":"Kristj\u00e1nsson","sequence":"first","affiliation":[{"name":"Faculty of Medicine, University of Iceland, 101 Reykjavik, Iceland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sigurdur","family":"Olafsson","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Landspitali\u2014The National University Hospital of Iceland, 101 Reykjavik, Iceland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2465-0422","authenticated-orcid":false,"given":"Magn\u00fas","family":"Gottfredsson","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Iceland, 101 Reykjavik, Iceland"},{"name":"Department of Infectious Diseases, Landspitali\u2014The National University Hospital of Iceland, 101 Reykjavik, Iceland"},{"name":"Department of Science, Landspitali\u2014The National University Hospital of Iceland, 101 Reykjavik, Iceland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thorvardur Jon","family":"Love","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Iceland, 101 Reykjavik, Iceland"},{"name":"Department of Science, Landspitali\u2014The National University Hospital of Iceland, 101 Reykjavik, Iceland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8392-0632","authenticated-orcid":false,"given":"Einar Stef\u00e1n","family":"Bj\u00f6rnsson","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Iceland, 101 Reykjavik, Iceland"},{"name":"Division of Gastroenterology and Hepatology, Landspitali\u2014The National University Hospital of Iceland, 101 Reykjavik, Iceland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,6,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1358\/dof.2011.36.9.1641618","article-title":"Targeting the NS5A protein of HCV: An emerging option","volume":"36","author":"Cordek","year":"2011","journal-title":"Drugs Future"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Di Marco, L., La Mantia, C., and Di Marco, V. (2022). Hepatitis C: Standard of Treatment and What to Do for Global Elimination. Viruses, 14.","DOI":"10.3390\/v14030505"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1111\/joim.12740","article-title":"Treatment as Prevention for Hepatitis C (TraP Hep C)\u2014A nationwide elimination programme in Iceland using direct-acting antiviral agents","volume":"283","author":"Tyrfingsson","year":"2018","journal-title":"J. Intern. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/S2468-1253(21)00137-0","article-title":"Treatment as Prevention for Hepatitis C (TraP HepC). Report on cascade of care during the first 36 months of a nationwide program in Iceland","volume":"6","author":"Olafsson","year":"2021","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"17562848221140657","DOI":"10.1177\/17562848221140657","article-title":"Update on the role of elastography in liver disease","volume":"15","author":"Ferraioli","year":"2022","journal-title":"Ther. Adv. Gastroenterol."},{"key":"ref_6","first-page":"4961919","article-title":"Long-Term Impact of Hepatitis C Virus Eradication on Liver Stiffness in Egyptian Patients","volume":"2021","author":"Zakareya","year":"2021","journal-title":"Can. J. Gastroenterol. Hepatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.jhep.2020.05.050","article-title":"Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension","volume":"73","author":"Lens","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Abu-Freha, N., Abu-Kosh, O., Yardeni, D., Ashur, Y., Abu-Arar, M., Yousef, B., Monitin, S., Weissmann, S., and Etzion, O. (2023). Liver Fibrosis Regression and Associated Factors in HCV. Patients Treated with Direct-Acting Antiviral Agents. Life, 13.","DOI":"10.3390\/life13091872"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J. Chronic Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s11901-017-0343-0","article-title":"Alcohol Consumption in Concomitant Liver Disease: How Much is Too Much?","volume":"16","year":"2017","journal-title":"Curr. Hepatol. Rep."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.jhep.2019.11.012","article-title":"Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysis","volume":"72","author":"Hajarizadeh","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1093\/cid\/ciaa105","article-title":"Concurrent Initiation of Hepatitis C and Opioid Use Disorder Treatment in People Who Inject Drugs","volume":"71","author":"Rosenthal","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1093\/cid\/ciac272","article-title":"High Rate of Hepatitis C Virus Reinfection Among Recently Injecting Drug Users: Results from the TraP Hep C Program\u2014A Prospective Nationwide, Population-Based Study","volume":"75","author":"Johannesson","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"100381","DOI":"10.1016\/j.clinsp.2024.100381","article-title":"Noninvasive assessment of liver fibrosis can predict clinical outcomes at late follow-up after a sustained virological response in HCV patients?","volume":"79","author":"Ragazzo","year":"2024","journal-title":"Clinics"},{"key":"ref_15","first-page":"1184","article-title":"Multiparametric liver assessment in patients successfully treated for hepatitis C: A 4-year follow-up","volume":"59","author":"Mulabecirovic","year":"2024","journal-title":"J. Gastroenterol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1111\/liv.12628","article-title":"Clinical application of transient elastography in patients with chronic viral hepatitis receiving antiviral treatment","volume":"35","author":"Kim","year":"2015","journal-title":"Liver Int."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1053\/j.gastro.2017.06.012","article-title":"Risk of Hepatocellular Cancer in HCV Patients Treated with Direct-Acting Antiviral Agents","volume":"153","author":"Kanwal","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1080\/00365521.2024.2345384","article-title":"Incidence of cirrhosis in Iceland\u2014Impact of the TraP HepC nationwide HCV elimination program","volume":"59","author":"Haraldsson","year":"2024","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e38096","DOI":"10.1097\/MD.0000000000038096","article-title":"Sustained virological response in chronic hepatitis C patients by direct-acting antiviral treatment significantly reduces liver stiffness over 24 weeks posttreatment","volume":"103","author":"Sirinawasatien","year":"2024","journal-title":"Medicine"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cgh.2017.04.038","article-title":"Magnitude and Kinetics of Decrease in Liver Stiffness After Anti-viral Therapy in Patients with Chronic Hepatitis C: A Systematic Review and Meta-analysis","volume":"16","author":"Singh","year":"2018","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1177\/2050640618786067","article-title":"Long-term changes in liver elasticity in hepatitis C virus-infected patients with sustained virologic response after treatment with direct-acting antivirals","volume":"6","author":"Pietsch","year":"2018","journal-title":"United Eur. Gastroenterol. J."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2147\/HMER.S142600","article-title":"Impact of hepatitis C virus genotype-4 eradication following direct acting antivirals on liver stiffness measurement","volume":"9","author":"Sabra","year":"2017","journal-title":"Hepatic Med. Evid. Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1111\/apt.14554","article-title":"Viral eradication reduces both liver stiffness and steatosis in patients with chronic hepatitis C virus infection who received direct-acting anti-viral therapy","volume":"47","author":"Tada","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s43066-023-00239-x","article-title":"Impact of HCV eradication following direct-acting antivirals on liver stiffness measurement: A prospective longitudinal study","volume":"13","author":"Ray","year":"2023","journal-title":"Egypt. Liver J."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Ferreira, J., Bicho, M., and Serejo, F. (2024). Effects of HCV Clearance with Direct-Acting Antivirals (DAAs) on Liver Stiffness, Liver Fibrosis Stage and Metabolic\/Cellular Parameters. Viruses, 16.","DOI":"10.3390\/v16030371"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00535-024-02165-0","article-title":"Histological improvement of fibrosis in patients with hepatitis C who achieved a 5-year sustained virological response to treatment with direct-acting antivirals","volume":"60","author":"Iwamoto","year":"2025","journal-title":"J. Gastroenterol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Lin, G.S., Mei, C.Y., Thompson, A.J., Christensen, B., Cunningham, G., McDonald, L., Bell, S., Iser, D., Nguyen, T., and Desmond, P.V. (2017). Sustained virological response halts fibrosis progression: A long-term follow-up study of people with chronic hepatitis C infection. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0185609"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.dld.2018.02.010","article-title":"Hepatocellular carcinoma risk assessment by the measurement of liver stiffness variations in HCV cirrhotics treated with direct-acting antivirals","volume":"50","author":"Ravaioli","year":"2018","journal-title":"Dig. Liver Dis."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/11\/3982\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:46:58Z","timestamp":1760032018000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/11\/3982"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,5]]},"references-count":28,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["jcm14113982"],"URL":"https:\/\/doi.org\/10.3390\/jcm14113982","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,5]]}}}